1. Market Research
  2. > Healthcare Market Trends
  3. > Healthcare Analysis & Statistics 2020 - European Union

Healthcare Analysis & Statistics 2020 - European Union

1-30 of about 400 reports

Hemophilia disease forecast and market analysis to 2035, Pharma Intelligence

  • $ 22000
  • July 2020
  • 86 pages

Disease Overview Hemophilia is a relatively rare hereditary genetic disorder characterized by an inability to produce a clot capable of stopping bleeding. Patients without hemophilia who develop inhibitors ...

  • Blood Disease
  • Healthcare
  • European Union
  • United States
  • Forecast

Olympus Corp (7733) - Product Pipeline Analysis, 2020 Update

  • $ 750
  • July 2020
  • 42 pages

Summary Olympus Corp (Olympus) provides precision machinery and instruments.The company develops, manufactures and markets equipment and devices for medical, healthcare, imaging, information, and othe ...

  • Artificial Intelligence
  • Endoscope
  • Healthcare
  • European Union
  • Olympus Corporation

Continuous Glucose Monitoring: The Current State of the Art

  • $ 3950
  • April 2020
  • 76 pages

Report Scope: The scope of this study includes what a CGM is, how it works and how a PWD wears the device.This study also includes advances in the technology—both those advances being seen in the market ...

  • Diabetes Monitoring
  • Healthcare
  • Patient Monitoring
  • European Union
  • United States

EU Healthcare Predictions and Outlook, 2020

  • $ 4950
  • February 2020
  • 56 pages

Amid rising global trade tensions and sluggish global economic outlook for 2020, the global healthcare market is expected to cross the 2-trillion-dollar mark in 2020. In Europe, BREXIT is likely to have ...

  • Diagnostics
  • Healthcare
  • European Union
  • World
  • Market Size

Market Spotlight: Obesity

  • $ 1318
  • February 2020
  • 62 pages

This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of ...

  • Healthcare
  • Obesity
  • Pathology
  • European Union

Directory of African Research Centres 2020

  • $ 295
  • January 2020
  • 170 pages

As medical device quality assurance and regulatory affairs professionals, it can be challenging to stay on top of changes happening in our industry. Few people have the time to read lengthy articles these ...

  • Healthcare
  • Medical Device
  • European Union
  • United States
  • Demand

International Directory of Medical Devices & Diagnostics Companies 2020

  • $ 375
  • January 2020
  • 500 pages

As medical device quality assurance and regulatory affairs professionals, it can be challenging to stay on top of changes happening in our industry. Few people have the time to read lengthy articles these ...

  • Healthcare
  • Medical Device
  • Medical Equipment
  • European Union
  • Demand

The State of Personalized/ Precision Medicine

  • $ 7995
  • October 2019
  • 119 pages

The State of Personalized/ Precision Medicine Summary Personalized and precision medicines use information about a person’s genes, proteins, and environment to prevent, diagnose, and treat disease.In ...

  • Healthcare
  • European Union
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.

Stivarga

  • $ 10000
  • September 2019
  • 30 pages

Drug Overview Stivarga (regorafenib; Bayer/Amgen) is an orally available small molecule inhibitor that is currently approved for the treatment of previously treated hepatocellular carcinoma patients. It ...

  • Colorectal Cancer
  • Healthcare
  • Hepatitis
  • Pathology
  • European Union

Nexavar

  • $ 10000
  • September 2019
  • 28 pages

Drug Overview Nexavar (sorafenib; Bayer/Amgen) is an orally available, multi-targeted tyrosine kinase inhibitor that is directed against several targets, including CRAF, BRAF, RET, KIT, FMS-like tyrosine ...

  • Healthcare
  • Hepatitis
  • Renal Cancer
  • European Union
  • United States

Lenvima

  • $ 10000
  • September 2019
  • 29 pages

Drug Overview Lenvima (lenvatinib; Eisai/Merck and Co) is an orally available small molecule inhibitor of multiple tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR), platelet-derived ...

  • Healthcare
  • Hepatitis
  • Pathology
  • Renal Cancer
  • European Union

Tecentriq

  • $ 10000
  • September 2019
  • 114 pages

Drug Overview Tecentriq (atezolizumab; Roche/Chugai) is a fully humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1). PD-L1 is expressed on the surface of antigen-presenting cells ...

  • Cancer
  • Healthcare
  • European Union
  • United States
  • Demand

Opdivo

  • $ 10000
  • September 2019
  • 118 pages

Drug Overview Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) is a fully human immunoglobulin G4 PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated ...

  • Cancer
  • Healthcare
  • Pathology
  • European Union
  • United States

Cyramza

  • $ 10000
  • September 2019
  • 65 pages

Drug Overview Cyramza (ramucirumab; Eli Lilly) is a fully human vascular endothelial growth factor receptor (VEGFR)-2-directed immunoglobulin G1 monoclonal antibody that binds to the extracellular domain ...

  • Cancer
  • Healthcare
  • Hepatitis
  • Pathology
  • European Union

Imfinzi

  • $ 10000
  • September 2019
  • 57 pages

Drug Overview Imfinzi (durvalumab; AstraZeneca) is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The interaction between PD-L1 and its receptor, programmed death-1 (PD-1), ...

  • Healthcare
  • Hepatitis
  • Lung Cancer
  • European Union
  • Demand

Keytruda

  • $ 10000
  • September 2019
  • 141 pages

Drug Overview Keytruda (pembrolizumab; Merck and Co) is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, ...

  • Cancer
  • Healthcare
  • Pathology
  • European Union
  • Japan

Cabometyx

  • $ 10000
  • September 2019
  • 29 pages

Drug Overview Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) is an orally available small molecule inhibitor which has been shown to suppress tumor growth and metastasis by inhibiting the activity of ...

  • Healthcare
  • Hepatitis
  • Renal Cancer
  • European Union
  • Supply

Nimenrix

  • $ 10000
  • September 2019
  • 13 pages

Drug Overview Nimenrix (quadrivalent polysaccharide tetanus toxoid conjugate vaccine; Pfizer) is a conjugated polysaccharide vaccine indicated for active immunization to prevent invasive meningococcal ...

  • Healthcare
  • Meningococcal
  • Vaccine
  • European Union
  • Market Description

MenABCW-135Y

  • $ 10000
  • September 2019
  • 12 pages

Drug Overview GlaxoSmithKline’s MenABCW-135Y is a pentavalent meningococcal conjugate vaccine for the A, B, C, W-135, and Y meningococcal strains. With all of the vaccine’s announced Phase II trials ...

  • Healthcare
  • Pathology
  • Vaccine
  • European Union
  • Product Initiative

Menveo

  • $ 10000
  • September 2019
  • 12 pages

Drug Overview Menveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline) is a quadrivalent meningococcal glycoconjugate vaccine that uses CRM-197, a natural mutant of the ...

  • Healthcare
  • Meningococcal
  • Vaccine
  • European Union
  • Forecast

Bexsero

  • $ 10000
  • September 2019
  • 13 pages

Drug Overview Bexsero (multicomponent meningococcal serogroup B vaccine; GlaxoSmithKline) is a multicomponent meningococcal serogroup B vaccine. It is approved for the prevention of invasive meningococcal ...

  • Healthcare
  • Meningococcal
  • Vaccine
  • European Union
  • United States

Dovato

  • $ 10000
  • June 2019
  • 14 pages

Dovato ([dolutegravir + lamivudine]; ViiV Healthcare) is a single-tablet regimen approved in the US for the treatment of HIV-1 infection in patients who are treatment-naïve. It is also being developed ...

  • Healthcare
  • HIV AIDS
  • Therapy
  • European Union
  • United States

Juluca

  • $ 10000
  • June 2019
  • 14 pages

Juluca ([dolutegravir + rilpivirine]; ViiV Healthcare/Johnson and Johnson) is a single-tablet regimen approved in the US for the treatment of patients infected with HIV-1 who have achieved viral supp ...

  • Antiviral
  • Healthcare
  • Therapy
  • European Union
  • United States

leronlimab

  • $ 10000
  • June 2019
  • 14 pages

Leronlimab (CytoDyn) is a humanized monoclonal antibody directed against C-C chemokine receptor 5 (CCR5), which is a co-receptor required for the attachment and entry of CCR5-tropic HIV-1 viruses into ...

  • Healthcare
  • HIV AIDS
  • Medical Biotechnology
  • European Union
  • United States

Stribild

  • $ 10000
  • June 2019
  • 16 pages

Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Japan Tobacco) is a single-tablet regimen for the treatment of HIV-1 infection. It is a co-formulation of marketed ...

  • Healthcare
  • Therapy
  • European Union
  • Japan
  • United States

Tivicay

  • $ 10000
  • June 2019
  • 26 pages

Tivicay (dolutegravir; ViiV Healthcare) is a once-daily, unboosted integrase inhibitor (INI) for the treatment of HIV-1 infection.

  • Healthcare
  • HIV AIDS
  • Therapy
  • European Union
  • United States

Complera

  • $ 10000
  • June 2019
  • 15 pages

Complera (rilpivirine/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Johnson and Johnson) is a single-tablet regimen for the treatment of HIV-1 infection.

  • Healthcare
  • HIV AIDS
  • Therapy
  • European Union
  • United States

Atripla

  • $ 10000
  • June 2019
  • 14 pages

Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.

  • Healthcare
  • HIV AIDS
  • Therapy
  • European Union
  • United States

Isentress

  • $ 10000
  • June 2019
  • 14 pages

Isentress (raltegravir; Merck and Co) is a twice-daily, unboosted integrase inhibitor (INI) that is used in combination with other antiretroviral drugs for treatment of HIV-1 infection.

  • Healthcare
  • HIV Antiviral
  • Therapy
  • European Union
  • United States

Genvoya

  • $ 10000
  • June 2019
  • 15 pages

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]; Gilead) is a single-tablet regimen (STR) approved for the treatment of HIV-1 infection.

  • Healthcare
  • Hepatitis Treatment
  • Therapy
  • European Union
  • United States
About 1400 reports

Download Unlimited Documents from Trusted Public Sources

View report >

Healthcare Industry - Analyst Report, June 2020

  • June 2020
  • 10 pages
  • Healthcare
  • Pathology
  • European Union
  • United States

Social Analysis May 2020


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on